Approaches that can break the interaction between SARS-CoV-2 and KIM1, including anti-KIM1 antibodies, small-molecule inhibitors, and KIM1-derived antagonist peptides, may shed light on COVID-19 treatment. This evidence concerns the gene HAVCR1 and COVID-19.